In the ever-evolving landscape of biotechnology and pharmaceuticals, Ivan Kairatov stands as a respected authority, particularly in tech and innovation within the biopharma sector. He joins us today to discuss recent developments concerning a compound known as inidascamine. Originally developed by
Emerging at the intersection of biotechnology and artificial intelligence, Absci is positioning itself as a transformative entity in the drug discovery landscape. This strategic positioning comes as the company recently announced a significant $50 million capital raise, a maneuver that underscores
Johnson & Johnson (J&J) is making significant strides in immunology drug development by embracing a pathway-centric approach to redefining autoimmune disease treatment under the leadership of Dr. Katie Abouzahr. This strategy diverges from traditional methods by prioritizing a multi-indication
The landscape of drug discovery, particularly for complex neurodegenerative diseases like ALS (Amyotrophic Lateral Sclerosis), is undergoing rapid transformation with the advent of artificial intelligence. Louisiana is making significant strides in this arena with the inception of the Louisiana AI
Ivan Kairatov is a renowned Biopharma expert with a wealth of experience in research and development, particularly at the intersection of technology and innovation in the field. Today, he shares insights into the groundbreaking research conducted at the University of Florida on developing a
Menstrual blood, often considered merely a byproduct of a natural biological process, is gaining attention as a potential source for health diagnostics. This innovative approach to using menstrual blood, rather than traditional venipuncture blood tests, opens new avenues for understanding and
